Topical DGLA-EE Composition for Inflammatory Skin Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic skin diseases like atopic dermatitis, such as steroids and FK-506, have significant side effects and there is a need for a safer, effective topical agent.
Innovation Solution
A composition for external use on skin containing dihomo-γ-linolenic acid ethyl ester (DGLA-EE) as an active ingredient, formulated in various forms including glycerides, phospholipids, alkyl esters, or free fatty acids, applied continuously to affected areas for at least 7 consecutive days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids or FK-506 are used as external agents for inflammatory skin diseases, then anti-inflammatory action is improved, but side effects worsen
Solution Approach 1:
The patent extracts and utilizes only the beneficial anti-inflammatory properties of natural fatty acids (γ-linolenic acid and dihomo-γ-linolenic acid) while eliminating the harmful side effects associated with synthetic steroids and immunosuppressants. The composition applies these naturally occurring fatty acids topically to achieve anti-inflammatory effects without the systemic side effects of conventional drugs.
Solution Approach 2:
The patent employs naturally occurring, readily available fatty acids that can be continuously applied without accumulating harmful effects. These natural compounds serve as replaceable, safe alternatives to potent but hazardous medications, allowing repeated topical application to maintain therapeutic effects without side effect accumulation.
2Object-generated harmful factors
If γ-linolenic acid or DGLA is used as external agent for skin disease, then safety is improved, but therapeutic efficacy worsens
Solution Approach 1:
The patent changes the chemical parameter by using dihomo-γ-linolenic acid (20:3 n-6) instead of the more common γ-linolenic acid (18:3 n-6). This parameter change results in a compound with extended carbon chain and additional double bonds, which provides both safety and enhanced therapeutic efficacy for inflammatory skin conditions.
Solution Approach 2:
The patent creates a composite topical composition that combines dihomo-γ-linolenic acid with specific carriers and adjuvants to enhance penetration and efficacy. The formulation includes compounds that work synergistically to improve delivery of the active fatty acid to inflamed skin tissues, thereby achieving both safety and therapeutic effectiveness.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided is a composition for use in the treatment of inflammatory disease by external use on skin, which comprises dihomo-γ-linolenic acid ethyl ester (DGLA-EE) as an active ingredient. The composition is safe to use and has anti-inflammatory and anti-allergic actions.